IGF1R and gastric cancer: Recently, in a mouse model of gastric cancer, the combination of treatment with antiangiogenic agent (bevacizumab) and genetic blockade of IGF-1 (IGF-1R dominant negative) efficiently reduced tumor growth and importantly resulted in the complete regression of 43% of tumors by inhibiting both angiogenesis and lymphangiogenesis [114].